{"id":"W2896077012","doi":"10.1016/j.jalz.2018.06.1391","title":"P3‐036: REPURPOSING OF MONTELUKAST FOR THE TREATMENT OF ALZHEIMER'S DISEASE: INTELGENX INITIATES PHASE 2A MONTELUKAST VERSAFILM™ CLINICAL TRIAL IN ALZHEIMER'S PATIENTS","year":2018,"lang":"en","type":"article","venue":"Alzheimer s & Dementia","topic":"Alzheimer's disease research and treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Cégep de Saint-Laurent","funders":"","keywords":"Montelukast; Medicine; Placebo; Clinical trial; Tolerability; Pharmacology; Internal medicine; Adverse effect; Alternative medicine; Pathology; Asthma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001565099,0.0009391494,0.001087507,0.0004384506,0.0003523232,0.001377571,0.0008769784,0.002146894,0.008104026],"category_scores_gemma":[0.0008142336,0.000346866,0.001221811,0.0002109058,0.0005861237,0.0009504288,0.0004866637,0.003346185,0.002041667],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005050525,"about_ca_system_score_gemma":0.001101604,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005704081,"about_ca_topic_score_gemma":0.001086582,"domain_scores_codex":[0.9996949,0.00009127185,0.00001539877,0.00005197251,0.00006922029,0.00007727363],"domain_scores_gemma":[0.9996092,0.00005306261,0.00006355404,0.00002873706,0.00004755476,0.0001980058],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2229831,0.04373137,0.004409862,0.00290524,0.001037488,0.001948246,0.0007276633,0.001785381,0.208349,0.003556947,0.06619651,0.4423693],"study_design_scores_gemma":[0.3565643,0.4340802,0.02555755,0.0006829234,0.001167561,0.004003442,0.0001911498,0.004902141,0.06804337,0.002718382,0.1019203,0.0001686552],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9290536,0.0215591,0.004096431,0.006881624,0.001429196,0.008948315,0.008350122,0.001137849,0.01854388],"genre_scores_gemma":[0.9197403,0.01603473,0.01452114,0.01154255,0.0008977838,0.006130753,0.01101228,0.000266543,0.01985405],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008104026,"threshold_uncertainty_score":0.0271107,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1166508924025112,"score_gpt":0.41232270658849,"score_spread":0.2956718141859788,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}